Pulmonary aspergillosis

George Richard Thompson, Thomas F. Patterson

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

As the population of patients with prolonged neutropenia, those receiving hematopoietic stem cell transplantation or lung transplantation, or those with human immunodeficiency virus or acquired immunodeficiency syndrome continues to increase, the rising incidence of pulmonary aspergillosis is unlikely to diminish. Aspergillus species are ubiquitous in nature, have no geographic predilection, and the spectrum of disease they cause is myriad, ranging from noninvasive disease with colonization to disseminated disease with an associated high mortality rate. The extent of disease is thus largely responsible for both the choice and the duration of antifungal therapy. Recent years have seen an expansion of antifungal agents, with efficacy against Aspergillus requiring an understanding of the full spectrum of disease for them to be used appropriately. Diagnosis is often difficult because existing tests lack desired sensitivity or specificity.

Original languageEnglish (US)
Pages (from-to)103-110
Number of pages8
JournalSeminars in Respiratory and Critical Care Medicine
Volume29
Issue number2
DOIs
StatePublished - Apr 2008
Externally publishedYes

Keywords

  • Aspergillus fumigatus
  • Pulmonary aspergillosis
  • Voriconazole

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Critical Care

Fingerprint Dive into the research topics of 'Pulmonary aspergillosis'. Together they form a unique fingerprint.

  • Cite this